On May 13, 2024, TaiMed's board of directors resolved to approve the company's financial report for the first quarter of 2024. The operating income was NT$178,948 thousand, an increase of approximately 1.5 times compared with NT$71,767 thousand in the same period last year; the net loss for the current period was NT$16,039 thousand, compared with NT$71,767 thousand in the same period the previous year. Compared with the net loss of NT$80,805 thousand in the same period the previous year, the loss was reduced by about 80%; the net loss per share was NT$0.06, which was significantly reduced compared with the net loss of NT$0.32 in the same period last year. By the end of the first quarter of 2024, the company has completed a cash capital increase of NT$1.64 billion, and the net value per share has increased from the original NT$10.14 to NT$15.42, which has significantly improved the financial structure. The net loss in the first quarter of 2024 was NT$16,039 thousand, including employee stock subscription compensation cost with no cash outflow for the cash capital increase of NT$14,260 thousand. If this part of the impact is deducted, the operation in this quarter is close to breaking even at profit and loss, which is the highest level in the past. According to the company's cash flow statement for the first quarter, the cash inflow from operating activities was NT$27,389 thousand, proving that this quarter's operating results have achieved positive net cash inflow.

Back to the top